Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.0001. Anthera Pharmaceuticals shares last traded at $0.0001, with a volume of 4,050 shares.

Anthera Pharmaceuticals Stock Performance

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, trading on the OTC Markets under the symbol ANTH, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for patients suffering from serious and rare inflammatory and autoimmune diseases. The company’s research and development efforts center on both biologic and small-molecule approaches designed to modulate key pathways in immune system dysfunction. Anthera’s strategy includes advancing lead candidates through late-stage clinical trials while exploring additional indications for its pipeline assets.

The company’s most advanced asset, blisibimod, is a selective antagonist of B-cell activating factor (BAFF) that has been evaluated in clinical studies for systemic lupus erythematosus (SLE) and primary immune thrombocytopenia (ITP).